The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2-induced radioresistance in HeLa cells expressing wild-type RAS

Radiat Res. 1999 Oct;152(4):404-11.

Abstract

In this paper, we describe the effect of the inhibitor of farnesyltransferase (FTI-277) on radioresistance induced by the 24-kDa isoform of FGF2 in human cells expressing wild-type RAS. Treatment with FTI-277 (20 microM) for 48 h prior to irradiation led to a significant decrease in survival of radioresistant cells expressing the 24-kDa isoform (HeLa 3A) but had no effect on the survival of control cells (HeLa PINA). The radiosensitizing effect of FTI-277 is accompanied by a stimulation of postmitotic cell death in HeLa 3A cells and by a reduction in G(2)/M-phase arrest in both cell types. These results clearly demonstrate that at least one farnesylated protein is involved in the regulation of the radioresistance induced by the 24-kDa isoform of FGF2. Furthermore, the radiation-induced G(2)/M-phase arrest is also under the control of farnesylated protein. This work also demonstrates that FTase inhibitors may be effective radiosensitizers of certain human tumors with wild-type RAS.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Alkyl and Aryl Transferases / antagonists & inhibitors*
  • Cell Survival / drug effects
  • Cell Survival / radiation effects
  • Enzyme Inhibitors / pharmacology*
  • Farnesyltranstransferase
  • Fibroblast Growth Factor 2 / antagonists & inhibitors*
  • HeLa Cells
  • Humans
  • Methionine / analogs & derivatives*
  • Methionine / pharmacology
  • Radiation Tolerance / drug effects*

Substances

  • Enzyme Inhibitors
  • FTI 277
  • Fibroblast Growth Factor 2
  • Methionine
  • Alkyl and Aryl Transferases
  • Farnesyltranstransferase